SCHEMBL651254

SCHEMBL651254

CC(=O)Nc1ncc(C=C2SC(=Nc3ccc4nc[nH]c4c3)NC2=O)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.41
KMT2A Q03164 10/20 0.41
MEN1 O00255 9/20 0.41
LMNA P02545 3/20 0.41
POLB P06746 3/20 0.40
PSMD14 O00487 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTPN11 Q06124 1/20 0.39
MAPK1 P28482 2/20 0.38
CDC25A P30304 1/20 0.38
CDC25B P30305 1/20 0.38
PLA2G1B P04054 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 2/20 0.37
HCRTR1 O43613 1/20 0.37
CCNE1 P24864 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651253 0.93 MAPT (0.41) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL652095 0.87 OGA (0.42) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL652094 0.87 OGA (0.42) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL650970 0.84 MAPT (0.41) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL10227936 0.84 MAPT (0.41) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL651290 0.84 OGA (0.47) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL651291 0.84 OGA (0.47) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL650969 0.84 MAPT (0.41) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649111 0.84 MAPT (0.40) MAPTKMT2AMEN1LMNAPOLB
SCHEMBL649110 0.84 MAPT (0.40) MAPTKMT2AMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885KMT2A 3437/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.